Giiant Pharma

About:

Giiant Pharma is a preclinical-stage biotech company.

Top Investors: Fonds de solidarité FTQ, Amorchem, AQC Capital, Amplitude Venture Capital, CQDM

Description:

Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Total Funding Amount:

$13.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Montréal, Quebec, Canada

Founded Date:

2014-01-01

Contact Email:

info(AT)giiant.com

Founders:

Elizabeth Kwong

Number of Employees:

1-10

Last Funding Date:

2023-12-28

IPO Status:

Private

Industries: